BIRC2 and non-small cell lung carcinoma: Moreover, IAP-2 as a novel putative biomarker was introduced for choosing paclitaxel rather than gemcitabine for the platinum-based doublets, which are still used as perioperative treatments in patients with early-stage NSCLC and silenced RASSF1A.